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Abstract
Background: The spatial relationship of glioblastoma (GBM) to the subventricular zone (SVZ) is associated with
inferior patient survival. However, the underlying molecular phenotype is largely unknown. We interrogated an
SVZ-dependent transcriptome and potential location-specific prognostic markers.
Methods: mRNA microarray data of a discovery set (n = 36 GBMs) were analyzed for SVZ-dependent gene expression
and process networks using the MetaCore™ workflow. Differential gene expression was confirmed by qPCR in a
validation set of 142 IDH1 wild-type GBMs that was also used for survival analysis.
Results: Microarray analysis revealed a transcriptome distinctive of SVZ+ GBM that was enriched for genes associated
with Notch signaling. No overlap was found to The Cancer Genome Atlas’s molecular subtypes. Independent validation
of SVZ-dependent expression confirmed four genes with simultaneous prognostic impact: overexpression of HES4
(p = 0.034; HR 1.55) and DLL3 (p = 0.017; HR 1.61) predicted inferior, and overexpression of NTRK2 (p = 0.049; HR 0.66)
and PIR (p = 0.025; HR 0.62) superior overall survival (OS). Additionally, overexpression of DLL3 was predictive
of shorter progression-free survival (PFS) (p = 0.043; HR 1.64). Multivariate analysis revealed overexpression of
HES4 to be independently associated with inferior OS (p = 0.033; HR 2.03), and overexpression of DLL3 with
inferior PFS (p = 0.046; HR 1.65).
Conclusions: We identified four genes with SVZ-dependent expression and prognostic significance, among those
HES4 and DLL3 as part of Notch signaling, suggesting further evaluation of location-tailored targeted therapies.
Keywords: Glioblastoma, Subventricular zone, mRNA microarray analysis, Location-dependent prognostic markers,
Notch signaling
Background
Despite recent advances in multimodal treatment, de
novo glioblastoma (GBM) World Health Organization
(WHO) grade IV remains one of the most intractable
human cancers, with a median survival of less than
15 months [1] and few long-time survivors [2]. Extensive
efforts have been made to maximize the extent of resec-
tion (EOR) with simultaneous preservation of neurologic
function and quality of life [3, 4]. At the same time, there
are apparent advances in postoperative radiotherapy,
chemotherapy, antiangiogenic therapy, immunotherapy,
and targeted therapies [5, 6]. Nevertheless, recurrence
occurs almost inevitably, in most cases adjacent to the
resection cavity, leading to non-standardized salvage
therapies and ultimately to death. Treatment failure has
been attributed in part to the fact that GBM is not a mono-
clonal disease but is characterized by intra- and intertumoral
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heterogeneity, resulting in divergent clinical presentation
and response to treatment. In this context, several molecular
subtypes have been identified [7, 8] with distinct driver
mutations, prognostic impact, and prediction of treatment
response, including a glioma-CpG island methylator
phenotype (G-CIMP) [9] which is highly dependent on the
presence of mutations in the isocitrate dehydrogenase 1
(IDH1) gene and is associated with improved patient
outcome [10]. Tumor location with respect to distinct brain
regions reflects another important aspect of intertumoral
heterogeneity. In particular, vicinity of de novo GBM to the
subventricular zone (SVZ) lining the lateral ventricles, one
of the persisting neurogenic regions in the adult human
brain [11, 12], has been linked to inferior patient outcome
[13] and a distinct growth pattern. Lim et al. initially
reported a series of 53 de novo GBMs that were preopera-
tively classified by their vicinity to the SVZ into four groups.
Group I consisted of GBMs with the contrast-enhancing
(CE) lesion contacting the SVZ and infiltrating the cortex,
group II of tumors contacting the SVZ but not involving the
cortex, group III of GBMs not contacting the SVZ but
involving the cortex, and group IV of tumors neither
contacting the SVZ nor infiltrating the cortex [14]. Group I
GBMs were most likely to be multifocal at first diagnosis
and to recur distant from the resection cavity, while group
IV GBMs were always solitary lesions with recurrences
exclusively adjacent to the primary site. The authors
concluded that GBMs with (SVZ+) and without (SVZ–)
contact to the SVZ might arise from different cells of origin
and that SVZ+ GBMs might reflect tumors with a high
content of SVZ stem cells that have undergone malignant
transformation, a hypothesis that has rarely been explored
in detail. In one of the few studies addressing this issue so
far, Kappadakunnel et al. failed to identify a stem cell-
derived gene signature by means of a DNA microarray
analysis of 47 GBMs classified according to their
relationship to the SVZ [15]. In contrast, in a phylo-
genetic approach making use of intraoperative
fluorescence-guided multiple sampling (FGMS) of hu-
man GBMs and their adjacent (fluorescent) SVZs,
Piccirillo et al. were able to identify the SVZ as a res-
ervoir of malignant precursor clones in the majority
of tumors analyzed [16]. Accordingly, several clinical
studies have provided evidence that targeting the ipsi-
lateral SVZ by irradiation is associated with superior
survival in patients with GBM [17, 18], especially in
combination with gross total resection (GTR) [19],
supporting the hypothesis that the SVZ plays a role
in GBM formation and propagation.
Even though SVZ+ GBMs appear to be associated with
a distinct clinical and radiographic behavior, little is
known about the molecular phenotype underlying these
characteristics and potential biomarkers linked to this
particular tumor location. Therefore, the aim of this
study was to identify a gene signature distinctive of de
novo GBM in vicinity to the SVZ and to discover
location-dependent genes with a potential prognostic
impact. Noteworthy, validation of differential gene ex-
pression and prognostic relevance was performed in a
confirmatory patient cohort restricted to IDH wild-type
(wt) GBM, excluding the unique molecular and prognos-
tic phenotype of IDH mutant (mt) GBM.
Methods
Clinical data
All demographic, treatment-related, and outcome data for
patients with de novo GBM treated at the Department of
Neurosurgery (University Hospital, Heidelberg, Germany)
between 1998 and 2011 were obtained through review of
medical charts and gathered in our institutional database.
Approval from the ethics committee and written informed
consent from patients were obtained in all cases and in ac-
cordance with the Declaration of Helsinki. EOR was deter-
mined for each patient on magnetic resonance imaging
(MRI) scans taken within 72 hours post surgery and was
deemed GTR if no residual contrast enhancement was
detected; otherwise, EOR was classified as “subtotal” or
“unknown” if no postoperative MRI was available. Radio-
graphic classification of GBMs according to their vicinity
to the SVZ was performed on preoperative contrast-
enhanced T1-weighed MR images as described by Lim et
al. [14] and depicted in Fig. 1. Group I consisted of tumors
contacting the SVZ and infiltrating the cortex, group II of
tumors contacting the SVZ only, group III of tumors con-
tacting the cortex only, and group IV of tumors contacting
neither SVZ nor cortex. Consequently, groups I and II tu-
mors were pooled as SVZ+ GBM, and groups III and IV
tumors as SVZ– GBM.
Microarray cohort
For microarray analysis, 36 patients with de novo GBM,
typical radiographic presentation according to the classi-
fication proposed by Lim et al. [14], and availability of
high-quality RNA (as described below) were investigated
(group I: n = 11, group II: n = 6, group III: n = 10, group
IV: n = 9). Median age at first diagnosis was 65 years;
median overall survival (OS) and progression-free
survival (PFS) were 11 and 3.5 months, respectively. All
patients had died by July 2014. The rate of GTR was
31 %. O6-methylguanine-DNA methyltransferase (MGMT)
promoter hypermethylation was detected in 56 % of
patients. IDH1 mutation was present in one patient only
(group III). There was no statistical difference regarding
age distribution, EOR, survival, and molecular characteris-
tics either between the four groups or when SVZ+ and
SVZ– GBMs were compared (Table 1).
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Validation cohort
For independent validation of microarray expression
data and evaluation of a prognostic significance of single
candidate genes, a validation set of 142 patients with
IDH1 wt GBM was analyzed (Table 1) for whom radio-
graphic classification was conducted as well. Median age
at first diagnosis was 62 years and median preoperative
Karnofsky performance score (KPS) was 82 %. Of these
patients, 31 % received GTR and the majority postopera-
tive radiation therapy (91 %). Temozolomide (TMZ) was
administered in two-thirds of patients. Median OS was
13 months and median PFS was 7 months. Seven pa-
tients were alive at the end of the study (July 2014) and
thus censored for survival analysis. MGMT promoter
hypermethylation was present in 26 %, absent in 37 %,
and not available in 37 % of patients.
Patient material, quality control, and RNA extraction
Tumor tissue was obtained following surgical resection
at the Department of Neurosurgery (University Hospital,
Heidelberg, Germany), immediately snap-frozen, and
stored at –80 °C until further processing. Due to the
retrospective nature of this study, the exact sampling
position with regard to distance to the SVZ was not de-
terminable; tumors were rather allocated to one of the
four location groups based on their radiographic appear-
ance. Two board-certified neuropathologists confirmed
histopathological diagnosis and quality control regarding
tumor content (>60 %) and necrosis (<20 %). Comparing
the distribution of tumor content between the four
location groups did not reveal a significant difference
(Additional file 1: Figure S1A). To ensure that differen-
tial gene expression in mRNA microarray analysis was
not affected by location-specific differences in tumor
microenvironment, we applied the ESTIMATE algo-
rithm from Yoshihara et al. [20], as described in detail in
Additional file 1: Figure S1B–D and Additional file 2.
IDH1 mutation and MGMT promoter methylation sta-
tus were determined as described elsewhere [2, 21, 22].
RNA was extracted with the AllPrep® DNA/RNA/Protein
mini kit (Quiagen, Hilden, Germany) according to the
Fig. 1 Flowchart illustrating the experimental design. De novo
glioblastomas were allocated to different radiographic groups
according to their vicinity to the SVZ as proposed by Lim et al. [14].
Group I consisted of contrast-enhancing tumors contacting the SVZ
and infiltrating the cortex, group II of tumors contacting the SVZ
only, group III of tumors contacting the cortex only, and group IV
of tumors contacting neither SVZ nor cortex. Accordingly, groups I
and II tumors were pooled as SVZ+ GBM, groups III and IV tumors
as SVZ– GBM. Location-dependent differential gene expression was
investigated by mRNA microarray analysis (microarray cohort; n = 36
GBM) and was validated by qPCR in a confirmatory patient sample
(validation cohort; n = 142 IDH1 wt GBM) with subsequent survival
analysis by log-rank test and multivariate Cox regression analysis
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Table 1 Patient characteristics of the microarray cohort (n = 36 GBMs) and the validation cohort (n = 142 IDH1 wt GBMs), presented
by location-dependent groups I–IV
Group I II III IV Total p value
Microarray cohort
Patients, n (%) 11 (30) 6 (17) 10 (28) 9 (25) 36
Sex, n (male : female) 5 : 6 6 : 0 7 : 3 5 : 4 23 : 13 0.14a
Age at diagnosis, mean (years) 68 64 59 64 65 0.21b
Extent of resection, n (%) 0.85a
- Complete 3 (27) 2 (33) 4 (40) 2 (22) 11 (31)
- Partial 4 (36.5) 4 (67) 5 (50) 5 (56) 18 (50)
- Unknown 4 (36.5) 0 1 (10) 2 (22) 7 (19)
OS, median (months) 9 9.5 15 16 11.5 0.98c
PFS, median (months) 3 5.5 3 5 3.5 0.47c
Multifocal CE lesion, n (%) 2 (18) 0 (0) 1 (10) 0 (0) 3 (8) 0.42a
Multifocal FLAIR lesion, n (%) 2 (18) 0 (0) 3 (30) 0 (0) 5 (14) 0.19a
MGMT promoter methylation, n (%) 0.06a
- Yes 9 (82) 1 (17) 6 (60) 4 (44) 20 (56)
- No 2 (18) 5 (83) 4 (40) 5 (56) 16 (44)
IDH1 mutation, n (%) 0.44a
- Yes 0 0 1 (10) 0 1 (3)
- No 11 (100) 6 (100) 9 (90) 9 (100) 35 (97)
Validation cohort
Patients, n (%) 49 (35) 17 (12) 66 (46) 10 (7) 142
Sex, n (male : female) 31 : 18 9 : 8 41 : 25 6 : 4 87 : 55 0.89a
Age at diagnosis, mean (years) 62 57 62 64 62 0.32d
KPS preoperative, mean 78 76 86 86 82 0.01d
Extent of resection, n (%) 0.006a
- Complete 8 (16) 6 (35) 23 (35) 7 (70) 44 (31)
- Partial 37 (76) 9 (53) 31 (47) 2 (20) 79 (56)
- Unknown 4 (8) 2 (12) 12 (18) 1 (10) 19 (13)
Radiation therapy, n (%) 43 (88) 16 (94) 62 (94) 8 (80) 129 (91) 0.4a
Temozolomide, n (%) 30 (61) 14 (82) 43 (65) 8 (80) 95 (67) 0.33a
OS, median (months) 12 14 15 17 13 0.004c
PFS, median (months) 6 8 7 8 7 0.27c
Censored patients, n (%) 2 (4) 1 (6) 4 (6) 0 (0) 7 (5) 0.85a
MGMT promoter methylation 0.43a
- Yes, n (%) 10 (20) 7 (41) 17 (26) 4 (40) 38 (26)
- No, n (%) 16 (33) 6 (35) 27 (41) 3 (30) 52 (37)
- Unknown, n (%) 23 (47) 4 (24) 22 (33) 3 (30) 52 (37)
IDH1 mutation, n (%) N/A
- No, n (%) 49 (100) 17 (100) 66 (100) 10 (100) 142(100)
OS overall survival, PFS progression-free survival, CE contrast-enhancing, FLAIR fluid attenuated inversion recovery, MGMT O6-methylguanine-DNA methyltransferase,
IDH1 isocitrate dehydrogenase 1, KPS Karnofsky performance score
aChi-square test
bKruskal-Wallis test
cLog-rank test
dOne-way ANOVA
N/A not applicable
In bold: p < 0.01
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manufacturer’s instructions from high-quality tissue sam-
ples. Analyte concentration and quality were determined
using a Nanodrop 2000 spectrophotometer (Thermo
Scientific) and a Bioanalyzer 2100 (Agilent), respectively.
Processing of microarray data
1 μg total RNA from 36 GBM tissues was submitted to
the Genomics Core Facilities of the German Cancer Re-
search Center (DKFZ, Heidelberg, Germany) for micro-
array analysis. After purification, reverse transcription to
cDNA, and labeling according to the Illumina protocol
[23], samples were hybridized to Human HT-12 v.4.0 ar-
rays (Illumina). Raw-intensity data were obtained after
image analysis of the fluorescent spot intensity reads. All
preprocessing and normalization steps were performed
in the R programming environment [www.r-project.org].
Interarray normalization was conducted using qspline
normalization in the affy package [24, 25]. After median
probe set summarization, a linear model was fitted to ac-
count for different batches (limma package). Lastly,
intraarray normalization was performed by median cen-
tering of the data, followed by log2 transformation. Data
were deposited at the NCBI Gene Expression Omnibus
[GEO:GSE83537].
Assessment of molecular subtypes in microarray cohort
Centroids established by Verhaak et al. [8] for subtyping
of GBM expression data were downloaded from The
Cancer Genome Atlas (TCGA) working group website
(the accompanying data freeze was released with the
aforementioned publication). For each case, correlation
(Pearson’s r) between respective expression values and
centroids was calculated for all genes available in the
data set (n = 800 out of 840). Subsequently, each sample
was assigned the subtype of the centroid with which it
was most strongly correlated.
Real-time PCR
Quantitative PCR (qPCR) was performed to confirm
mRNA microarray expression data and differential expres-
sion of single candidate genes in the validation cohort. Pri-
mer design and selection of corresponding hybridization
probes was done using the Universal ProbeLibrary Assay
Design Center (http://lifescience.roche.com). Primers were
obtained from Sigma-Aldrich (St. Louis, MO, USA) and
along with the probes are summarized in Additional file 3:
Table S1. RT-PCR reactions were performed according to
the manufacturer’s instructions using 45 amplification
cycles (LightCycler LC480, cDNA First Strand Transcrip-
tor Kit, LightCycler TaqMan Master, Universal ProbeLi-
brary Set (human); all Roche Diagnostics, Mannheim,
Germany). Quantification of mRNA expression was
performed in triplicate and referenced to a set of house-
keeping genes: glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), beta-actin (ACTB), and hypoxanthine-guanine
phosphoribosyltransferase 1 (HPRT1). Only triplicates with
a deviation in crossing point (Cp) values of less than <0.55
were deemed appropriate for further relative quantification
employing qbase + software version 2.5 (Biogazelle NV,
Zwijnaarde, Belgium).
Statistical analyses
Unless stated otherwise, statistical analyses were con-
ducted in R (www.r-project.org). Differential gene
expression in GBM subgroups was assessed using a two-
sided Student’s t test and a Mann-Whitney test as
indicated. For survival analysis, PFS and OS were used
as end points. PFS was defined as the time interval from
first histologic diagnosis to radiologic signs of progres-
sion/recurrence or death, whatever occurred first. OS
was defined as the time interval from first histologic
diagnosis until death or last follow-up. Prognostic sig-
nificance was determined using univariate and multivari-
ate Cox regression analyses and log-rank tests. For
multivariate models, all clinico-pathological parameters
significant in the univariate analysis were included.
Enrichment analysis for process networks was performed
using the MetaCore™ analysis workflow.
Results
SVZ-dependent transcriptional profiles in de novo GBM
First, an mRNA microarray analysis was performed for a
discovery set of 36 de novo GBMs (microarray cohort)
allocated to one of the four radiographic groups pro-
posed by Lim et al. [14]. Hierarchical clustering of the
top 222 genes differentially expressed between SVZ+
and SVZ– GBMs (p < 0.01) revealed distinct transcrip-
tional profiles that perfectly discriminated between these
two groups (Fig. 2a). This effect was most pronounced
when only the two most contrary GBM groups (group II
(contacting SVZ only) and group III (contacting cortex
only)) that separate best between GBMs with and with-
out SVZ involvement were compared (top 312 genes; p
< 0.01) (Fig. 2b). To learn more about the functional
significance of these gene signatures, a MetaCore™ en-
richment analysis was performed to identify the top 10
pathways associated with differential gene expression.
Enrichment analysis of the top 1494 genes differentially
expressed between SVZ+ and SVZ– GBMs (p < 0.05) re-
vealed upregulation of genes linked to chromatin modifi-
cation and downregulation of genes linked to Notch
signaling, blood vessel morphogenesis, and immune
modulation (T cell receptor signaling, interleukin-2 (IL-2)
signaling, leukocyte chemotaxis) in SVZ+ GBMs (Table 2).
Comparing the top 1573 genes differentially expressed be-
tween group II and group III GBMs (p < 0.05), genes re-
lated to neurogenesis were upregulated, and genes related
to blood vessel morphogenesis and immune modulation
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Fig. 2 a, b Hierarchical clustering of mRNA microarray data revealed two main transcriptional profiles that reflect the allocation of tumors
according to their vicinity to the SVZ in general (a; top 222 genes differentially expressed between SVZ+ and SVZ– GBMs (p < 0.01)) and to group
II (GBMs contacting the SVZ only) and group III (GBMs contacting the cortex only) tumors in particular (b; top 312 genes; p < 0.01). c There was
no overlap between location-dependent (SVZ+/–) gene signatures and the molecular subtypes reported by the TCGA working group. d Box
plots depicting differential expression of genes considered as stem cell markers, lineage markers, and markers of three developmental pathways
(Notch, Wnt, Sonic Hedgehog (SHH)) as identified by mRNA microarray analysis. Note that significant differences (p < 0.05; marked with asterisk)
were observed for a subset of genes only (FZD6, PTCH2, NOTCH2, HES4, NEFH) together with a strong trend for DLL3 (p = 0.0654), notably including
three genes with involvement of Notch signaling
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(IL-2 signaling, leukocyte chemotaxis) were downreg-
ulated in group II GBMs contacting the SVZ only
(Table 3). We further explored a potential overlap be-
tween SVZ-dependent transcriptomes and the mo-
lecular subtypes reported by the TCGA working
group [8] but found none (Fig. 2c).
Identification of candidate genes distinctive of SVZ+ GBM
To identify single candidate genes with location-
dependent differential expression, mRNA microarray data
were further compared between SVZ+ and SVZ– GBMs
and group II and group III GBMs, respectively. Candidate
genes had to meet the following criteria: a p value
(two-sided t test) of <0.01 and/or a log2 fold change
(FC) of >0.5/<–0.5 in at least one of the two compar-
isons (Fig. 1). Thus, 26 genes were identified (Table 4).
To exclude false positive results, qPCR analysis of
mRNA expression was performed for all tumor samples of
the microarray cohort. Differential gene expression on
a p < 0.05 level (two-sided Mann-Whitney test) was veri-
fied for 16 genes: PIR (pirin), HES4 (hairy and enhancer of
split 4), DLL3 (delta-like 3), NTRK2 (neurotrophic recep-
tor tyrosine kinase type 2), IGFBP5 (insulin-like growth
factor-binding protein 5), BAI3 (brain-specific angiogen-
esis inhibitor 3), EMILIN-3 (elastin microfibril interfacer
3), FERMT2 (fermitin family member 2), CDH4 (cadherin
4), HIF1A (hypoxia inducible factor 1, alpha subunit),
RBP1 (retinol binding protein 1), SYTL4 (synaptotagmin-
like 4), THBS4 (thrombospondin 4), FZD6 (frizzled class
receptor 6), ENPP5 (ectonucleotide pyrophosphatase/
phosphodiesterase 5), and BATF3 (basic leucine zipper
transcription factor, ATF-like 3). See Table 4. Two of these
genes (EMILIN-3 and CDH4) have never been reported in
the context of glioma research so far. BATF3 had to be
Table 2 Summary of enrichment analysis for the top 1494 differentially expressed genes between groups I, II (SVZ+) versus III, IV
(SVZ–) (p < 0.05)
MetaCoreTM process network Upregulated in SVZ+ (n = 771) Downregulated in SVZ+ (n = 723)
Term p value (nupregulated/ntotal) p value (ndownregulated/ntotal)
Blood vessel morphogenesis 0.669 (4/228) 1.55E-04 (16/228)
Regulation of epithelial-to-mesenchymal transition 0.943 (2/226) 4.57E-04 (15/226)
Leukocyte chemotaxis 0.985 (1/205) 5.32E-04 (14/205)
Chromatin modification 9.61E-04 (9/128) 0.392 (4/128)
T cell receptor signaling 0.971 (1/174) 1.22E-03 (12/174)
Cytoskeleton - actin filaments 0.465 (4/176) 1.35E-03 (12/176)
Notch signaling 0.507 (5/236) 2.08E-03 (14/236)
0.480 (4/144)
Skeletal muscle development 2.19E-03 (9/144)
Cell cycle G1/S 0.407 (4/163) 2.31E-03 (11/163)
Inflammation - IL-2 signaling 0.878 (1/104) 4.11E-03 (8/104)
The top 10 enrichments according to p value are depicted (in bold: p < 0.01). In addition, the total number of genes per process network (ntotal) as well as the
intersect with significantly up- or downregulated genes are displayed (nupregulated and ndownregulated)
Table 3 Summary of enrichment analysis for the top 1573 differentially expressed genes between groups II and III (p < 0.05)
MetaCoreTM process network Upregulated in group II (n = 957) Downregulated in group II (n = 616)
Term p value (nupregulated/ntotal) p value (ndownregulated/ntotal)
Blood vessel morphogenesis 0.058 (10/228) 2.14E-07 (20/228)
Muscle contraction 1.22E-03 (12/173) 0.411 (7/173)
Male sex differentiation 0.087 (10/246) 1.50E-03 (14/246)
Transmission of nerve impulse 2.36E-03 (13/212) 0.360 (6/212)
Neurogenesis 2.95E-03 (12/192) 0.452 (5/192)
Chemotaxis 0.669 (3/137) 4.13E-03 (9/137)
Anti-apoptosis via PI3K/Akt 0.982 (2/233) 7.16E-03 (12/233)
Leukocyte chemotaxis 0.891 (3/205) 7.36E-03 (11/205)
Neurohormone signaling 0.273 (7/211) 9.06E-03 (11/211)
Inflammation - IL-2 signaling 0.482 (3/104) 9.73E-03 (7/104)
The top 10 enrichments according to p value are depicted (in bold: p < 0.01). In addition, the total number of genes per process network (ntotal) as well as the
intersect with significantly up- or downregulated genes are displayed (nupregulated and ndownregulated)
PI3K phosphatidylinositide 3-kinase, Akt protein kinase B
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excluded from further analysis in the validation cohort
due to a negative correlation of expression data, and
FZD6 and ENPP5 due to a high variance of expression
values. All other genes (n = 13) were subjected to an inde-
pendent validation of differential gene expression by
means of qPCR in the validation cohort (n = 142 patients
with IDH1 wt GBM).
As expected, independent validation of location-
dependent differential expression was accomplished for
a subset of genes only. In SVZ+ GBMs, upregulation of
HES4 (p = 0.01) was observed, a finding that was even
more pronounced (p = 0.0007) when group II GBMs
(contacting the SVZ only) were compared to group III
GBMs (contacting the cortex only). In group II GBMs,
there was also a strong trend for upregulation of DLL3
(p = 0.086) and NTRK2 (p = 0.056) and downregulation
of PIR (p = 0.05) (Table 4; Fig. 3a, b).
SVZ-dependent regulation of genes involved in Notch
signaling
It has been hypothesized that de novo GBMs with and
without contact to the SVZ are derived from different
cells of origin with SVZ+ GBMs enriched for (cancer)
stem cells [11, 12, 14]. In this study, MetaCore™ pathway
analysis of mRNA microarray data did not reveal enrich-
ment in classical (cancer) stem cell pathways except for
a downregulation of genes linked to Notch signaling in
SVZ+ GBMs (Table 2). When comparing the two most
contrary location-specific groups II and III by means of
MetaCore™, Notch signaling was not among the top
Table 4 Tabular summary of SVZ-dependent expression of genes
Gene Microarray cohort (n = 36) Selected
for validation
Validation cohort (n = 142)
SVZ+ vs. SVZ– II vs. III SVZ+ vs. SVZ– II vs. III Expression in SVZ+/II
p value FC qPCR p value FC qPCR p value p value
PIR 0.0188 0.4770 0.0082 0.0047 0.7338 0.0225 ✓ 0.1597 0.05 Low
HES4 0.3680 −0.0135 0.0015 0.0440 −0.5945 0.5584 ✓ 0.0102 0.0007 High
DLL3 0.5645 −0.7725 0.1407 0.0654 −1.5897 0.0295 ✓ 0.9516 0.0857 High (trend)
NTRK2 0.0511 0.2464 0.5821 0.0304 0.5708 0.0559 ✓ 0.7883 0.0558 High (trend)
IGFBP5 0.0134 0.4772 0.0066 0.0234 1.2149 0.1179 ✓ 0.8477 0.9498 –
BAI3 0.3676 −0.0817 0.1829 0.0290 −0.5699 0.0714 ✓ 0.2911 0.8653
EMILIN3 0.0810 0.3924 0.3921 0.0290 0.7203 0.0312 ✓ 0.6789 0.5567
FERMT2 0.0109 −0.1693 0.0058 0.0088 −0.8139 0.0017 ✓ 0.7765 0.1156
CDH4 0.0197 −0.3874 0.0168 0.0929 −0.7704 0.0120 ✓ 0.2006 0.7516
UCHL1 0.0168 0.3306 0.1369 0.2702 0.1823 0.7063
HIF1A 0.0052 −0.1433 0.0215 0.1274 −0.1174 0.5345 ✓ 0.6371 0.7699
TGFB3 0.0021 −0.5547 0.2056 0.0570 −0.6072 0.3000
RBP1 0.0017 0.6986 0.0186 0.0035 1.2351 0.0312 ✓ 0.9776 0.6936
SYTL4 0.1318 0.0785 0.2347 0.0035 1.0968 0.0075 ✓ 0.3189 0.4702
THBS4 0.0155 0.1638 0.1810 0.0096 0.8009 0.0072 ✓ 0.4495 0.9817
NODAL 0.0043 −0.4242 0.3117 0.0225 −0.4279 0.2625
FZD6 0.1895 0.1517 0.4073 0.0014 0.6362 0.0730
VAV3 0.0873 0.1032 0.5665 0.0235 0.8138 0.4895
ENPP5 0.3551 0.2665 0.0397 0.0218 0.6382 0.0116
TIMP4 0.4696 0.1804 0.1286 0.0417 0.5615 0.1179
NDN 0.0107 0.8016 0.2038 0.2543 1.3415 0.9458
NFKBIA 0.0149 −0.1440 0.3924 0.0144 −0.3358 0.2515
IRF9 0.0750 −0.0766 0.2604 0.0157 −0.5397 0.2630
BATF3 0.1257 −0.1263 0.0414 0.0087 −0.6015 0.6570
ANGPTL2 0.2385 −0.1070 0.5178 0.0187 −0.6711 0.7632
PDGFRA 0.9394 −0.0442 0.2959 0.0453 −1.1161 0.0714
First, mRNA microarray data were compared between SVZ+ and SVZ– GBM and group II and group III GBM, respectively (in bold: p < 0.01 (two-sided t test), log2
fold change (FC) >0.5/<–0.5) with technical validation of differential gene expression by qPCR (in bold: p < 0.05 (two-sided Mann-Whitney test)) (microarray cohort).
Based on the prespecified significance levels, 13 candidate genes (indicated by check marks) were chosen for validation of differential gene expression by qPCR
(in bold: p < 0.05 (two-sided Mann-Whitney test)) in a confirmatory patient cohort (validation cohort)
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Fig. 3 a, b Box plots illustrating differential expression of candidate genes in the validation cohort as confirmed by qPCR. a Significant overexpression
of HES4 in SVZ+ GBMs. b Significant overexpression of HES4 in group II GBMs. Also, there was a strong trend towards overexpression of DLL3 and
NTRK2 in group II GBMs and PIR in group III GBMs. c Location-dependent prognostic significance of NTRK2 in SVZ+ GBMs (left panel) as well as NTRK2
(middle panel) and DLL3 (right panel) in group II GBMs. Superior OS was observed in patients with ≥75 % expression of NTRK2 (Q1 cut-off) and <50 %
expression of DLL3 (median cut-off), respectively
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signaling networks, but group II GBMs were enriched
for genes related to neurogenesis (Table 3). Keep in
mind, however, that a significant p value for the enrich-
ment analysis does not necessarily imply a meaningful
down- or upregulation of the pathway, but a mere en-
richment of the differentially upregulated or downregu-
lated genes for the respective process network (Tables 2
and 3). As enrichment analyses with a curated gene list
or process networks can only serve as a starting point
for further analysis, we decided to hand-search our
mRNA microarray data for an additional selection of 47
published markers of neural stem cells, radial glia cells,
and brain tumor-initiating cells (BTICs), lineage markers
and key players of three developmental pathways
(Notch, Wnt, Sonic Hedgehog) in view of a potential
location-dependent difference in gene expression. In this
regard, we chose to compare groups II and III GBMs
since this represents the most distinct separation be-
tween GBMs with (group II) and without (group III)
contact to the SVZ (Fig. 2d). However, an unequivocal
SVZ-dependent (cancer) stem cell signature was not de-
tected. In fact, differential gene expression was observed
for a subset of genes only (FZD6, NOTCH2, PTCH2 and
HES4, DLL3, NEFH, respectively). Notably, three of
these genes (DLL3, NOTCH2, HES4) are involved in
Notch signaling: DLL3 is a ligand to Notch receptors
(among those NOTCH2), while HES4 is a target gene of
Notch signaling that acts as a tissue-specific repressor
(Fig. 4). This observation prompted us to search our
microarray data for further components of the Notch
pathway. Indeed, a non-significant differential regula-
tion was found for PSEN2 (presenilin2) and NCSTN
(nicastrin), two genes involved in the intracellular cleavage
of Notch receptors, and for MAML3 (mastermind like
transcriptional coactivator 3) that amplifies Notch-
induced transcription (Fig. 4). For HES4 and DLL3, SVZ-
dependent differential gene expression was confirmed
in further analyses of the validation cohort (Table 4;
Fig. 3a, b), along with a significant prognostic impact
on patient outcome (Table 5), as described below.
Identification of prognostic markers distinctive of SVZ+ GBM
In our validation cohort of 142 patients with IDH wt
GBM, age at first diagnosis, radiotherapy, adjuvant
chemotherapy, preoperative KPS and GTR, together with
a clear trend for SVZ involvement (p = 0.056; HR 1.39
(0.99–1.96)), were predictive for OS, while age at first
diagnosis and adjuvant chemotherapy were predictive for
PFS (Table 5). In the multivariate analysis, vicinity to the
SVZ (SVZ+ GBM) was an independent prognosticator
of inferior OS (p = 0.023; HR 1.82 (1.09–3.04); 12 ver-
sus 15 months) but did not affect PFS (Table 5). As
expected from the literature, GTR was an independ-
ent prognosticator of superior OS (p = 0.007; HR 0.48
(0.29–0.83)). Note that the rate of GTR was signifi-
cantly higher in SVZ– GBM compared to SVZ+ GBM
(39 % versus 21 %; p = 0.019; Fisher’s exact test).
Radiotherapy (p = 0.002; HR 0.22 (0.08–0.58)) and age
at first diagnosis (p = 0.024; HR 1.03 (1.00–1.06)) were
also associated with OS in the multivariate analysis.
Next, we asked if our location-specific candidate genes
discovered by microarray analysis (HES4, DLL3, NTRK2,
PIR) conferred a prognostic impact; therefore, we inves-
tigated a possible association between mRNA expression
levels and patient outcome in the validation cohort.
Since nothing is known about the biological power of
candidate gene expression levels, expression data were
dichotomized both according to the median in “high”
and “low” expression (“median cut-off”) and according
to quartiles either in “top 25 % expression” and “<75 %
expression” (“Q1 cut-off”) or “bottom 25 % expression”
and “>25 % expression” (“Q3 cut-off”). Univariate analysis
revealed a prognostic impact for all of these genes. High
expression of HES4 (p = 0.034, HR 1.55 (1.03–2.32); Q3
cut-off) and DLL3 (p = 0.017, HR 1.61 (1.08–2.39); median
cut-off) predicted inferior OS, while high expression of
NTRK2 (p = 0.049, HR 0.66 (0.44–1.00); Q1 cut-off) and
Fig. 4 mRNA microarray analysis (microarray cohort; n= 36 GBMs)
revealed SVZ-dependent differential gene expression of key hierarchies
of the Notch pathway. Results are visualized comparing group II
(contacting the SVZ only) and group III (involving the cortex only)
GBMs, since this grouping discriminates most precisely between GBMs
with and without SVZ involvement. In group II GBMs, significant
overexpression (p< 0.05; highlighted in red) was observed for DLL3
(ligand to Notch receptors), NOTCH2 (Notch transmembrane receptor),
and HES4 (nuclear target gene to Notch signaling; tissue-specific
transcription repressor). For PSEN2 (presenilin2) and NCSTN (nicastrin),
two components of the presenilin-gamma-secretase complex that is
involved in cleavage of the intracellular Notch receptor domain, and
MAML3 (mastermind like transcriptional coactivator 3; amplifies
Notch-induced transcription), overexpression did not reach significance
(highlighted in yellow)
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PIR (p = 0.025, HR 0.62 (0.41–0.95); Q1 cut-off) predicted
superior OS. High expression of DLL3 was also predictive
of inferior PFS (p = 0.043, HR 1.64 (1.01–2.68); median
cut-off). See Table 5. Also, a negative prognostic impact
on OS was revealed for IGFBP5 (p = 0.015, HR 1.62
(1.09–2.39); Q1 cut-off ), one of the candidate genes
for which location-dependent gene expression could
not be confirmed in the validation cohort. Note that
NTRK2 and DLL3 were identified as location-specific
prognostic markers: in SVZ+ GBMs, OS was significantly
prolonged in patients with high NTRK2 expression levels
(p = 0.006; Q1 cut-off; 18.5 versus 10.5 months). In group
II GBMs, a significantly higher OS was observed in
patients with high NTRK2 expression (p = 0.042; Q1 cut-
off; 23 versus 8.5 months) and with low DLL3 expres-
sion (p = 0.046; median cut-off; 24 versus 13 months),
Table 5 Clinical and molecular prognostic factors of overall (OS) and progression-free (PFS) survival in the validation cohort (n = 142
IDH wt patients) based on a univariate log-rank test and a multivariate Cox regression model
OS PFS
HR (95 % CI) p value HR (95 % CI) p value
Univariate
Clinico-pathological parameters
Age at first diagnosis 1.05 (1.03–1.07) 4.0E-07 1.02 (1.00–1.04) 0.020
Gender (male) 0.99 (0.70–1.41) 0.971 1.33 (0.87–2.04) 0.187
Radiotherapy 0.29 (0.16–0.52) 9.7E-06 0.99 (0.31–3.13) 0.983
Chemotherapy 0.41 (0.28–0.59) 1.4E-06 0.58 (0.37–0.91) 0.017
Preoperative KPS 0.98 (0.97–0.99) 0.002 1.00 (0.99–1.01) 0.810
MGMT methylation 0.83 (0.53–1.29) 0.401 1.15 (0.69–1.92) 0.588
GTR 0.42 (0.28–0.62) 8.8E-06 0.78 (0.49–1.23) 0.286
Location (SVZ+) 1.39 (0.99–1.96) 0.056 1.07 (0.71–1.61) 0.743
Location (II vs. III) 1.19 (0.69–2.08) 0.526 1.30 (0.66–2.60) 0.445
Candidate genes
Cut-offs
IGFBP5 Q1 1.62 (1.09–2.39) 0.015 1.19 (0.73–1.94) 0.475
DLL3 Median 1.61 (1.08–2.39) 0.017 1.64 (1.01–2.68) 0.043
NTRK2 Q1 0.66 (0.44–1.00) 0.049 0.64 (0.39–1.07) 0.086
PIR Q1 0.62 (0.41–0.95) 0.025 0.66 (0.40–1.08) 0.092
HES4 Q3 1.55 (1.03–2.32) 0.034 1.31 (0.81–2.13) 0.268
Multivariate
Clinico-pathological parameters
Age at first diagnosis 1.03 (1.00–1.06) 0.024 1.01 (0.99–1.04) 0.198
Radiotherapy 0.22 (0.08–0.58) 0.002
Chemotherapy 0.55 (0.29–1.05) 0.072 0.62 (0.36–1.06) 0.082
Preoperative KPS 0.99 (0.98–1.01) 0.504
GTR 0.48 (0.29–0.83) 0.007
Location (SVZ+) 1.82 (1.09–3.04) 0.023
Candidate genes
Cut-offs
IGFBP5 Q1 0.82 (0.48–1.42) 0.488
DLL3 Median 1.47 (0.83–2.60) 0.181 1.65 (1.00–2.70) 0.046
NTRK2 Q1 0.75 (0.41–1.38) 0.358
PIR Q1 0.75 (0.41–1.36) 0.344
HES4 Q3 2.03 (1.06–3.90) 0.033
Gene expression data were dichotomized according to the median in “high” and “low” expression (“median cut-off”) and according to quartiles either in “top 25 %
expression” and “<75 % expression” (“Q1 cut-off”) or “bottom 25 % expression” and “>25 % expression” (“Q3 cut-off”). p values < 0.05 are displayed in bold letters
HR hazard ratio, CI confidence interval, KPS Karnofsky performance score, MGMT O6-methylguanine-DNA methytransferase, GTR gross total resection
Jungk et al. BMC Medicine  (2016) 14:170 Page 11 of 16
respectively (Fig. 3c). Most importantly, multivariate
survival analysis revealed a negative prognostic impact
of HES4 on OS (p = 0.033; HR 2.03 (1.06–3.9)), inde-
pendent of all other candidate genes and clinical fac-
tors with significant survival impact in univariate
analysis, and of DLL3 on PFS (p = 0.046; HR 1.65
(1.00–2.70)). See Table 5.
Taken together, our stepwise approach identified four
genes (HES4, DLL3, PIR, NTRK2) with SVZ-specific
expression and simultaneous prognostic significance
(summarized in Fig. 5). In multivariate survival analysis,
HES4 was an independent prognosticator of OS and DLL3
of PFS. Both overall pathway analysis and in-depth ana-
lysis of single candidate genes point to a relevant involve-
ment of Notch signaling in SVZ+ GBM.
Discussion
Intertumoral heterogeneity is one of the mainstays of
treatment failure in GMB; thus, there is a need for indi-
vidualized prognostication and treatment approaches.
Tumor location is one important aspect that clearly deter-
mines treatment options, functional outcome, and quality
of life. However, it is largely unknown whether tumor lo-
cation is linked to a distinct molecular phenotype. In this
study we sought to compare transcriptomes of GBMs with
and without spatial relationship to the SVZ in order to
identify location-dependent gene signatures and prognos-
tic markers. In contrast to previous studies, location-
dependent candidate genes identified in a discovery set
were validated in an independent patient cohort compris-
ing exclusively IDH wt GBM. Thereby, we sought to ex-
clude the unique molecular and prognostic phenotype of
IDH mt GBM [9].
Hierarchical clustering of microarray data revealed
two main transcriptional profiles that perfectly matched
the allocation of tumors according to their vicinity to
the SVZ in general and to group II (GBMs contacting
the SVZ only) and group III (GBMs contacting the cor-
tex only) tumors in particular. MetaCore™ enrichment
analysis linked these SVZ-dependent transcriptomes to
major pathways involved in cell growth and motility,
angiogenesis, immune modulation, and Notch signaling,
one of the major developmental pathways involved in
neural stem cell (NSC) maintenance and gliomagenesis
[26, 27]. Importantly, no overlap was found between our
location-specific transcriptional profiles and the four
molecular subgroups described by the TCGA [8]. In face
of our study’s relatively small case number, tumor vicin-
ity to the SVZ does not appear as a determining factor
of the TCGA’s molecular phenotypes.
Ever since the early reports that vicinity of GBM to
the SVZ is linked to a distinct growth behavior and in-
ferior patient outcome [13–15], it has been hypothesized
that SVZ+ GBM may arise from transformed NSCs ori-
ginally residing within the SVZ [11, 12]. Indeed there is
evidence from rodent studies that inactivation of typical
tumor suppressor genes (TP53, NF1, PTEN) allocates
formation and early progression of high-grade astrocy-
toma to neural stem/progenitor cells within the SVZ
[28–30]. In humans, intraoperative fluorescence-guided
multiple sampling (FGMS) along a spatial gradient
within the tumor mass and the adjacent (fluorescent)
SVZ recently allowed for a phylogenetic reconstruction
with SVZ-derived tumor precursor cells giving rise to
the tumor mass in the majority of GBM patients ana-
lyzed, and thus, for the first time, substantiated a role of
the SVZ in gliomagenesis in humans [16]. These obser-
vations also suggest that SVZ+ GBMs are enriched in
NSCs and BTICs, a hypothesis that has not yet been ex-
plored in much detail. In a microarray analysis of 47
GBMs, Kappadakunnel et al. did not find a correlation
between 7 selected stem cell-related genes of interest
(PROM1, MELK, BMP4, ETF2, MAPK8, OLIG2, NES)
and tumor location [15]. Instead, 7 of the 33 genes over-
expressed in group II tumors were related to immune
signaling (FCGR3A, HLA-DRB5, BCL6, FCGR3B, MAFB,
HLA-DRA, HLA-E), a finding which was underscored by
our MetaCore™ pathway analysis.
To further investigate a potential stem cell origin of
SVZ+ GMB, we searched our microarray data for
location-specific differential expression of a panel of 47
well-known NSC, BTIC, and lineage markers as well as
key players of three development pathways (Notch, Wnt,
and Sonic Hedgehog). Since group I GBMs that are de-
fined as SVZ+ GBMs consist of voluminous tumors that
reach from the cortical surface to the SVZ and, in the-
ory, may reflect tumors that originate from the cortex
rather than the SVZ, we decided to compare group II
and group III tumors only, since this reflects the most
concise regional separation between GBMs with (group
Fig. 5 Graphical summary of location-dependent differential gene
expression and identification of prognostic markers, comparing SVZ+
(groups I and II) and SVZ– (groups III and IV) GBMs and group II
(contacting the SVZ only) and group III (involving the cortex only)
GBMs, respectively
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II) and without (group III) SVZ contact. Differential
regulation of gene expression was observed for a subset
of genes only (FZD6, PTCH2, NEFH, NOTCH2, HES4,
DLL3), including three genes (NOTCH2, HES4, DLL3)
involved in Notch signaling. Remarkably, location-
dependent differential gene expression was detected at
all key hierarchies of the Notch pathway (depicted in
Fig. 4). It is well known that Notch signaling drives NSC
maintenance and differentiation of neural progenitor
cells into astroglia (reviewed in [27]). Moreover, aberrant
Notch pathway activation contributes to formation and
propagation of primary GBM [31], possibly through
propagation of the BTIC pool [32], and therapeutic in-
hibition of Notch signaling is under investigation both in
vitro and in vivo (reviewed in [33]). In this regard, our
study provides the first link between Notch expression
and tumor location. With the Notch ligand DLL3 and
the transcription factor HES4 we found pivotal upregu-
lated genes that later proved to be prognostic in a multi-
variate setting. However, our data are restricted to the
transcriptional level, and functional analyses are needed
to shed further light on location-specific Notch pathway
activation. Nevertheless, neither this analysis nor that of
Kappadakunnel et al. found unequivocal evidence of a
(cancer) stem cell signature in SVZ+ GBM [15]. This
may account for the fact that differential expression was
assessed on a transcriptional level only and that in-depth
analysis of a larger patient sample, in particular com-
bined with investigation of protein expression, may yield
unambiguous results. A sampling error may also come
into play. Since all samples were retrospectively identi-
fied from our tumor bank, it is impossible to reconstruct
the exact position of sampling, in particular with regard
to distance from the SVZ. Particularly in group I GBM,
the most voluminous location-specific subgroup extend-
ing from the SVZ throughout the white matter to cor-
tical areas, there may well be a spatial gradient in the
enrichment of tumor tissue with NSCs and BTICs, a fac-
tor impossible to take into account unless tissue sam-
pling is done in a prospective manner with multiple
samples derived from the same tumor and the regions of
interest defined on perioperative imaging [16, 34].
Ultimately, it would be worthwhile to compare tran-
scriptomes from SVZ+ and SVZ– GBMs to those de-
rived from non-malignant human SVZ to elucidate the
role of the SVZ in human gliomagenesis. However, to
the best of our knowledge, array data from human SVZ
tissue have been lacking until now.
To attenuate the sampling issue, we ensured that all
GBM tissues analyzed were homogeneous throughout
the location groups in terms of tumor content and inter-
play from the microenvironment (Additional file 1:
Figure S1A–D) and validated HES4 and DLL3 expression
together with 11 other top differentially expressed
candidate genes derived from microarray analysis in an
independent set of 142 IDH1 wild-type GBMs (valid-
ation cohort). Hence, we were able to confirm SVZ-
dependent expression of HES4 and DLL3. HES4 was sig-
nificantly overexpressed in both SVZ+ GBMs and group
II GBMs. HES4 is one of seven HES target genes of
Notch signaling that serve as tissue-specific transcription
repressors upon Notch pathway activation, leading to in-
hibition of cell differentiation and maintenance of stem
cell features [35]. Little is known about the particular
function of HES4 in stem cells and cancer. HES4 was
shown to keep retinal precursor cells of the Xenopus cil-
iary margin zone in an undifferentiated and slowly pro-
liferative state [36]. In human B cells, HES4 inhibits
early differentiation and acts as a tumor suppressor with
epigenetic silencing in B cell acute lymphoblastic
leukemia [37]. Recently, HES4 has been established as a
biomarker in advanced solid tumors, predicting treat-
ment response to Notch pathway inhibition by gamma-
secretase inhibitors [38, 39]. Notably, our analysis consti-
tutes the first report on HES4 interaction in human
brain tumors.
DLL3 is the second Notch pathway key player for
which a strong trend towards overexpression in group II
GBMs was confirmed in our analysis. DLL3 is a direct
ligand to Notch receptors, with conflicting data about its
activating or rather inhibiting role in Notch signaling
[40–44]. Likewise, DLL3 has been described in the
context of proneural GBM with inconsistent expression
patterns: according to Phillips et al. [7] and Verhaak et
al. [8], overexpression of DLL3 is a hallmark of pro-
neural GBM, while Cooper et al. [45] report loss of
DLL3 in proneural GBM. In the meantime, identification
of an IDH-dependent G-CIMP phenotype has further
separated the initially favorable appraised proneural
molecular subgroup into GBMs with an IDH-mutant, G-
CIMP-positive phenotype exhibiting a highly favorable
prognosis and an IDH-wild-type, non-G-CIMP pheno-
type with an exceedingly dismal prognosis [9]. This is of
importance, since none of the aforementioned studies
stratified expression and survival data for IDH mutation
status, while our study comprised IDH1 wt GBM only.
Indeed, DLL3 was significantly overexpressed in the 10
tumor samples of our microarray cohort assigned to the
proneural subtype (p = 0.0078; Mann-Whitney test; data
not shown), but no difference in OS was observed
between proneural and other subtypes (p = 0.4776; log-
rank test; data not shown).
We also observed a strong trend towards upregulation
of NTRK2 and downregulation of PIR in group II GBMs
(contacting the SVZ only). NTRK2 encodes for the
neurotrophic tyrosine kinase, receptor, type 2, also
known as Trk-B. Neurotrophins and their receptors are
crucial for cell growth, survival, and apoptosis in the
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nervous system [46], but expression has been observed
in glioma as well [47], even though their functional role
is largely unknown. Activation of Trk-B and Trk-C has
been shown to promote growth and survival of BTICs
independent of epidermal growth factor (EGF) and basic
fibroblast growth factor (bFGF) [48]. In our study,
NTRK2 overexpression was found in GBMs with SVZ
contact, possibly maintaining BTIC growth as well. PIR
is another location-specific candidate gene with down-
regulation observed in group II GBMs. It encodes for
the iron-binding nuclear protein pirin, a transcriptional
regulator, and has been described as an oncogene [49] and
promoter of metastatic tumor growth [50] on one hand
and as a tumor suppressor gene on the other [51] in many
solid cancers, but never before in glioma. In acute myeloid
leukemia (AML), PIR was linked to terminal differenti-
ation of myeloid precursors with a downregulation of PIR
possibly related to the differentiation arrest observed in
AML [52]. By contrast, overexpression of PIR was in-
volved in inhibition of cellular senescence in melanocytic
cells, resulting in transformation to melanoma [53]. In
GBM, the functional role of PIR has yet to be discovered.
Besides their SVZ-dependent expression, HES4, DLL3,
PIR, and NTRK2 also conferred a significant impact on
patient survival, together with known clinico-pathological
prognosticators. Importantly, the reported adverse effect
of SVZ involvement on OS [13] was confirmed in our
study sample by multivariate analyses. In line with its dis-
tinct expression in GBMs contacting the SVZ, HES4
turned out to be the most robust prognostic marker with
overexpression related to adverse OS, even overriding the
prognostic effect of all other molecular markers in the
multivariate analysis. As elucidated above, HES4 is a novel
molecular marker in GBM and underscores the biological
and clinical role of Notch pathway activation in primary
GBM, in particular in tumors involving the SVZ. Likewise,
overexpression of DLL3, the second molecular marker in-
volved in Notch signaling, resulted in significantly reduced
OS and PFS in the univariate analysis and turned out to
be an independent prognostic marker of inferior PFS in
the multivariate analysis. Moreover, high expression of
PIR and NTRK2 was associated with superior OS. It is
noteworthy that in patients with GBMs contacting the
SVZ (SVZ+ GBMs, group II GBMs), NTRK2 expression
levels were able to predict OS. The beneficial effect of
NTRK2 overexpression on OS confirms recent data
reporting that loss of mRNA expression of both NTRK1
and NTRK2 correlates with poor prognosis in patients
with high-grade glioma [54], but our analysis adds a
location-specific link to the picture. To our knowledge,
this is the first report on PIR as a prognostic marker in
GBM, with evidence of SVZ-dependent differential ex-
pression, and it is worth further functional analysis to in-
vestigate its role as an oncogenic or tumor repressive
factor. In addition to these four genes with SVZ-
dependent differential expression and concurrent prog-
nostic impact, we also identified IGFBP5 expression to be
inversely related to OS, even though a location-specific
expression could not be established. There is sparse evi-
dence from the literature that overexpression of IGFBP5
increases in a WHO grade-dependent fashion with highest
expression observed in GBM [55, 56] and a strong trend
linking overexpression to adverse OS [55]. The functional
role of IGFBP5 has not been fully clarified, but it may play
a role in tumor dormancy, among others in GBM [57].
Conclusions
In summary, this study revealed inherent transcriptional
differences of GBMs, depending on their vicinity to the
SVZ. Interestingly, all four genes with simultaneous
SVZ-dependent differential expression and significant
prognostic impact were characterized by their involve-
ment in stem cell maintenance. Two of these genes
(HES4, PIR) have never before been reported in the
context of gliomagenesis and deserve further functional
exploration. Importantly, Notch signaling was an out-
standing feature of SVZ+ GBM, with the two key players
HES4 and DLL3 identified as location-specific prognosti-
cators. Further work will be required, but this finding
suggests that SVZ+ GBM might profit most from the
therapeutic Notch inhibition that is currently under inves-
tigation in clinical trials. Mounting evidence is in favor of
location-tailored therapies, since irradiation of the ipsilat-
eral SVZ as a potential BTIC niche has been shown to
have a positive impact on patient outcome [17, 18], par-
ticularly in patients with GTR [19]. SVZ-specific targeted
molecular therapies might add another important piece to
the picture.
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in hematoxylin and eosin (HE) stain, (B) StromalScore, (C) ImmuneScore, and
(D) ESTIMATEScore between location groups. StromalScore, ImmuneScore,
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factor-binding protein 5; MGMT: O6-methylguanine-DNA methyltransferase;
mt: Mutant; NSC: Neural stem cell; NTRK2: Neurotrophic receptor tyrosine
kinase, type 2; OS: Overall survival; PFS: Progression-free survival; PIR: Pirin;
qPCR: Quantitative polymerase chain reaction; SVZ: Subventricular zone;
TCGA: The Cancer Genome Atlas; TMZ: Temozolomide; WHO: World Health
Organization; wt: Wild-type
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